

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
10 February 2005 (10.02.2005)

PCT

(10) International Publication Number  
**WO 2005/011628 A2**

(51) International Patent Classification?: **A61K 9/00**

[GB/GB]; 3 Maybelle Close, Beare Green Surrey RH5 4RJ (GB).

(21) International Application Number:  
**PCT/GB2004/003329**

(74) Agents: **HAYES, Adrian, Chetwynd et al., BOULT WADE TENNANT**, Verulam Gardens, 70 Gray's Inn Road, LONDON WC1X 8BT (GB).

(22) International Filing Date: 30 July 2004 (30.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0317869.6 30 July 2003 (30.07.2003) GB

(71) Applicant (for all designated States except US): **DISPERSE LIMITED** [GB/GB]; European Centre, Surrey Research Park, 40 Alan Turing Road, Guildford Surrey GU2 7YF (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHARMAN, William** [AU/AU]; Victorian College of Pharmacy, Monash University, 381 Royal Parade, Parkville, Victoria 3052 (AU). **DIAS, Monica** [PT/GB]; The Evergreens, Hambledon Park, Hambledon, Guildford Surrey GU8 4EP (GB). **GEORGIU, Michelle** [GB/GB]; 55 New Road, Chilworth Surrey GU4 8LP (GB). **GUFFOGG, Philip** [GB/GB]; 16 St Michael's Road, Ponsanooth, Truro Cornwall TR3 7EA (GB). **PORTER, Christopher** [GB/AU]; Victorian College of Pharmacy, Monash University, 381 Royal Parade, Parkville, Victoria 3052 (AU). **POUTON, Colin** [GB/AU]; Victorian College of Pharmacy, Monash University, 381 Royal Parade, Parkville, Victoria 3052 (AU). **STEELE, Fraser** [GB/AU]; Victorian College of Pharmacy, Monash University, 381 Royal Parade, Parkville, Victoria 3052 (AU). **WHEELER, Derek**

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

#### Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **IMPROVED DRUG DELIVERY SYSTEM**

(57) Abstract: An oral drug delivery system which comprises a biliquid foam comprising: from 1 to 20% by weight of a continuous hydrophilic phase, from 70 to 98% by weight of a pharmaceutically acceptable oil which forms a discontinuous phase, the said pharmaceutically acceptable oil having dissolved or dispersed therein a poorly water-soluble drug in an amount of from 0.1 to 20% by weight and the biliquid foam including therein from 0.5 to 10% by weight of a surfactant to enable the formation of a stable biliquid foam, all percentages being based upon the total weight of the formulation.

WO 2005/011628 A2